Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prostate cancer: Enzalutamide plus ADT maintains health-related QoL

Publish date:: June 11, 2020

Key clinical point: Enzalutamide plus androgen deprivation therapy (ADT) enables men with metastatic hormone-sensitive prostate cancer (mHSPC) to maintain their health-related quality of life (QoL).

Major finding: Enzalutamide+ADT vs. placebo+ADT significantly delayed time to first deterioration in worst pain (14.09 vs. 11.10 months; P = .032), pain severity (19.38 vs. 16.76 months; P = .021), and EuroQoL 5-Dimensions, 5-Levels visual analog scale score (11.14 vs. 8.38 months; P = .0070).

Study details: In this ARCHES phase 3 trial, 1,150 patients with mHSPC were randomly assigned to receive either enzalutamide (160 mg/day)+ADT (n = 574) or placebo+ADT (n = 576).

Disclosures: This study was funded by Astellas Pharma Inc. and Pfizer Inc. Some of the investigators reported consulting/advisory role and research funding from Astellas and consulting/advisory role for Pfizer during the conduct of the study.

Citation:

Stenzl A et al. Eur Urol. 2020 Apr 23. doi: 10.1016/j.eururo.2020.03.019.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Prostate Cancer

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,